How much funding has Spinifex Pharmaceuticals raised?

Spinifex Pharmaceuticals has raised $66.5M in total funding, most recently a Series C round.

Who are Spinifex Pharmaceuticals's investors?

Spinifex Pharmaceuticals's investors include Novo Holdings A/S, Uniseed, Brandon Capital Partners, Canaan Partners, Red Tree Venture Capital.

When was Spinifex Pharmaceuticals founded?

Spinifex Pharmaceuticals was founded in 2005.

Where is Spinifex Pharmaceuticals headquartered?

Spinifex Pharmaceuticals is headquartered in Melbourne, Australia.

What industry is Spinifex Pharmaceuticals in?

Spinifex Pharmaceuticals operates in Biotech.

Spinifex Pharmaceuticals

Acquired

Melbourne, Australia · Founded 2005 · $66.5M raised

Biotech

Headquarters: Melbourne
Founded: 2005
Business Model: B2B
Total Funding: $66.5M

Last Round: $45.0M Series CApr 2014
Rounds: 3
Acquired by: Novartis AGJun 2015

About

Spinifex Pharmaceuticals was a development-stage biopharmaceutical company founded in 2005 out of the University of Queensland, developing non-opioid treatments for chronic neuropathic pain. Its lead candidate, EMA401, was an oral angiotensin II type 2 receptor antagonist designed to block pain signals without central nervous system side effects. Novartis acquired the company in 2015 for roughly US$200 million upfront plus milestone payments, one of the largest venture-backed biotech exits in Australian history.

Summary

Spinifex Pharmaceuticals is a Biotech company based in Melbourne, Australia, founded in 2005. It has raised $66.5M in total across 3 rounds, most recently a $45.0M Series C round in Apr 2014. Investors include Novo Holdings A/S, Uniseed and Brandon Capital Partners.